Financial Summary (All financials)
| In millions, except per share items | Sep-30-15 | Sep-30-14 | Sep-30-13 | Sep-30-12 | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 |
| Revenues | 29.0 | 8.0 | 68.0 | 61.0 | 65.0 | 5,753.0 | 5,241.0 | 8,381.0 |
| Revenue growth | 262.5% | -88.2% | 11.5% | -6.2% | -98.9% | 9.8% | -37.5% | 7.7% |
| Cost of goods sold | 1,544.0 | 1,508.0 | 1,719.0 | 1,598.0 | 1,547.0 | 4,124.0 | 3,850.0 | 7,056.0 |
| Gross profit | -1,515.0 | -1,500.0 | -1,651.0 | -1,537.0 | -1,482.0 | 1,629.0 | 1,391.0 | 1,325.0 |
| Gross margin | -5224.1% | -18750.0% | -2427.9% | -2519.7% | -2280.0% | 28.3% | 26.5% | 15.8% |
| Selling, general and administrative | -1,550.0 | -1,503.0 | -1,721.0 | -1,600.0 | -1,550.0 | 1,338.0 | 1,399.0 | 1,118.0 |
| Research and development | | | | | | 78.0 | 96.0 | 48.0 |
| EBITA | 238.0 | -42.0 | 824.0 | 597.0 | 449.0 | 319.0 | -21.0 | 213.0 |
| EBITA margin | 820.7% | -525.0% | 1211.8% | 978.7% | 690.8% | 5.5% | -0.4% | 2.5% |
| Amortization of intangibles | 78.0 | 89.0 | 88.0 | 89.0 | 74.0 | 68.0 | 68.0 | |
| EBIT | 160.0 | -131.0 | 736.0 | 508.0 | 375.0 | 251.0 | -89.0 | 213.0 |
| EBIT margin | 551.7% | -1637.5% | 1082.4% | 832.8% | 576.9% | 4.4% | -1.7% | 2.5% |
| Pre-tax income | 169.0 | -116.0 | 749.0 | -43.0 | 3.0 | 75.0 | -323.0 | 261.0 |
| Income taxes | -22.0 | -188.0 | 196.0 | -57.0 | -53.0 | -13.0 | -83.0 | 86.0 |
| Tax rate | | 162.1% | 26.2% | 132.6% | | | 25.7% | 33.0% |
| Earnings from continuing ops | 191.0 | 72.0 | 553.0 | 14.0 | 56.0 | 88.0 | -240.0 | 175.0 |
| Earnings from discontinued ops | | | | | | 53.0 | -21.0 | -8.0 |
| Net income | 191.0 | 72.0 | 553.0 | 14.0 | 56.0 | 141.0 | -261.0 | 167.0 |
| Net margin | 658.6% | 900.0% | 813.2% | 23.0% | 86.2% | 2.5% | -5.0% | 2.0% |
| |
| Diluted EPS | $2.77 | $0.92 | $6.91 | $0.18 | $0.70 | $1.11 | ($3.33) | $2.76 |
| Shares outstanding (diluted) | 69.0 | 78.0 | 80.0 | 80.0 | 80.0 | 79.0 | 72.0 | 63.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|